about
Haemolymph from Mytilus galloprovincialis: Response to copper and temperature challenges studied by (1)H-NMR metabonomics.Telomerase inhibition and cancer: might platinum based drugs have a future as anti-telomerase pharmacological approach?Functionalized nonporous silica nanoparticles as carriers for Pt(iv) anticancer prodrugs.Antiproliferative activity of a series of cisplatin-based Pt(IV)-acetylamido/carboxylato prodrugs.Functional fluorescent nonporous silica nanoparticles as carriers for Pt(IV) anticancer prodrugs.Cellular trafficking, accumulation and DNA platination of a series of cisplatin-based dicarboxylato Pt(IV) prodrugs.Biological activity of a series of cisplatin-based aliphatic bis(carboxylato) Pt(IV) prodrugs: how long the organic chain should be?trans,cis,cis-bis(benzoato)dichlorido(cyclohexane-1R,2R-diamine)platinum(IV): a prodrug candidate for the treatment of oxaliplatin-refractory colorectal cancer.Antiproliferative activity of Pt(IV)-bis(carboxylato) conjugates on malignant pleural mesothelioma cells.The hexacarbonyldicobalt derivative of aspirin acts as a CO-releasing NSAID on malignant mesothelioma cells.Revisiting [PtCl₂(cis-1,4-DACH)]: an underestimated antitumor drug with potential application to the treatment of oxaliplatin-refractory colorectal cancer.Synthesis, characterization and antiproliferative activity on mesothelioma cell lines of bis(carboxylato)platinum(IV) complexes based on picoplatin.Synthesis, characterization, structure, molecular modeling studies and biological activity of sterically crowded Pt(II) complexes containing bis(imidazole) ligands.Platinum-bisphosphonate complexes have proven to be inactive chemotherapeutics targeted for malignant mesothelioma because of inappropriate hydrolysis.In vitro anti-mesothelioma activity of cisplatin-gemcitabine combinations: evidence for sequence-dependent effects.Biological activity of enantiomeric complexes [PtCl(2)L (2)] (L (2) is aromatic bisphosphanes and aromatic diamines).The relevance of polar surface area (PSA) in rationalizing biological properties of several cis-diamminemalonatoplatinum(II) derivatives.The influence of temperature on antiproliferative effects, cellular uptake and DNA platination of the clinically employed Pt(II)-drugs.Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line.Enhancement of the cytotoxicity of titanocene dichloride by aging in organic co-solvent.Cytotoxicity of cis-platinum(II) conjugate models. The effect of chelating arms and leaving groups on cytotoxicity: a quantitative structure-activity relationship approach.Water-soluble benzoheterocycle triosmium clusters as potential inhibitors of telomerase enzyme.Effect of arbuscular mycorrhizal and bacterial inocula on nitrate concentration in mesocosms simulating a wastewater treatment system relying on phytodepuration.Uptake of antitumor platinum(II)-complexes by cancer cells, assayed by inductively coupled plasma mass spectrometry (ICP-MS).Cis-[Pt(Cl)2(pyridine)(5-SO3H-isoquinoline)] complex, a selective inhibitor of telomerase enzyme.Water stability and cytotoxic activity relationship of a series of ferrocenium derivatives. ESR insights on the radical production during the degradation process.Polyanionic Biopolymers for the Delivery of Pt(II) Cationic Antiproliferative Complexes.Oxidative degradation of 1,5-naphthalenedisulfonic acid in aqueous solutions by UV-photolysis in the absence and presence of H2O2.Electrochemical measurements confirm the preferential bonding of the antimetastatic complex [ImH][RuCl(4)(DMSO)(Im)] (NAMI-A) with proteins and the weak interaction with nucleobases.Authentication and traceability study of hazelnuts from piedmont, Italy.The cadmium binding domains in the metallothionein isoform Cd(7)-MT10 from Mytilus galloprovincialis revealed by NMR spectroscopy.Molecular interaction fields vs. quantum-mechanical-based descriptors in the modelling of lipophilicity of platinum(IV) complexes.Synthesis and characterisation of estrogenic carriers for cytotoxic Pt(II) fragments: biological activity of the resulting complexes.Radical scavenging abilities of fish MT-A and mussel MT-10 metallothionein isoforms: An ESR study.The RP-HPLC measurement and QSPR analysis of logP(o/w) values of several Pt(II) complexes.Cisplatin and valproate released from the bifunctional [Pt(IV)Cl2(NH3)2(valproato)2] antitumor prodrug or from liposome formulations: who does what?An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate.May glutamine addiction drive the delivery of antitumor cisplatin-based Pt(IV) prodrugs?Molecular and statistical modeling of reduction peak potential and lipophilicity of platinum(IV) complexes.Antiproliferative Pt(IV) complexes: synthesis, biological activity, and quantitative structure–activity relationship modeling
P50
Q31048073-212DDDCE-F9EB-4F1C-AA2A-D6355A4A8022Q36352286-CD7E4E9C-B903-4C68-99FE-855B1634D8EDQ38734711-08C6766E-2CC5-43B3-A777-58E7FB53FAB4Q38791841-7A8B1954-3CE2-4965-BCEA-78009EFA98CEQ38843429-91E9BBA2-C530-45A0-A97F-B5280D960073Q38867690-465BDC10-D9B8-4F02-9636-B4D411A847D7Q38961699-E7746CBE-A347-429B-90BA-E3C0DE485AF4Q39006039-0D346C07-E117-4C1E-88D7-68B90C0AD573Q39089791-64A669D0-C00C-460C-9A63-5C96DF55EC38Q39093077-C2706296-982E-40E7-A674-C4094D548256Q39315864-90858D83-AEB5-4D9C-9CC9-56A1C056E618Q39404847-34662BB4-47C5-4A15-BB6C-8DBE99770150Q39573364-2938BA57-DDA1-4590-8647-B570EC27631CQ39589439-BD574C55-A3D1-4B12-8054-EEB1B78C4E00Q39718655-5F848A9A-B21A-42CA-9553-936C6FF8634BQ39723723-1F17E7D0-6328-4AAD-9C79-45F491098831Q39819988-3928AB13-5D2E-4BEB-BB5C-ABB149877CACQ40045005-41390C24-3070-4995-8C4A-CFA6A06D25C1Q40071039-6ECE0534-6C46-4F87-8E96-56CC1A9EB48BQ40364901-EE3F3549-B6BE-4D49-AFC5-534DBEC5EB65Q40462341-0A63F523-73FB-4D62-8ED6-D89615E4D840Q40476748-1DE2F405-4B64-4186-949E-48E016B255C9Q40481635-36A5D385-3E9F-4066-A89A-BB66008B346EQ40610067-6261F226-1F66-45DD-8259-1388C47CC578Q40643449-3A213441-BDD9-4E18-9DE2-01F9F1C93088Q40684054-B3874222-8512-4AE7-8442-D286B6BFFB63Q41429967-655735B4-9EAE-4129-BB12-BE40AD1354D2Q43166943-29F65C34-F190-4639-A4B5-9EAEEF735547Q44900841-B2B8DE53-7363-4924-8E2F-61D5F175E94CQ45385051-41087EF1-2DC3-4FE0-857B-76E3B29CE5A1Q46316770-BAA036D7-AAD8-4BB2-BBB7-24C894FD6343Q46569102-63734CD7-60C9-4241-B133-AD20A9E66C27Q46711805-6A1993D6-BC6F-46D0-96B6-051790693C4FQ46776200-83312AE1-5C75-422F-A4CC-057833582363Q46985575-2BB35B57-03FF-436B-AD14-21E588BCBA88Q48350344-5DA35FDB-B113-4479-9246-1B1CBA7215B0Q49563999-04717311-2AAF-4DD9-8B56-4EA0D181A081Q51297597-51188E0F-8DED-4189-BE69-5BD289AAC6DEQ53450886-99FE03DE-8362-4746-A736-FA6B5A5A666AQ57819324-F60F11CA-8421-4F72-AC12-D3963950F1BB
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Domenico Osella
@ast
Domenico Osella
@en
Domenico Osella
@es
Domenico Osella
@nl
type
label
Domenico Osella
@ast
Domenico Osella
@en
Domenico Osella
@es
Domenico Osella
@nl
prefLabel
Domenico Osella
@ast
Domenico Osella
@en
Domenico Osella
@es
Domenico Osella
@nl
P106
P1153
7003351953
P31
P496
0000-0002-6706-9454